Table 3: Analysis of clinical events.

Outcomes (comparisons)Treatment group (n/N)Control group (n/N)RR95% CI

(1) All-cause mortality
Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]126/2429189/24410.67
(2) Mortality of CHD
(2.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 134/24410.69
(2.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Guan 2010 [22] 6/640.15
Lou et al. 2008 [28] 1/410.95
Overall (FEM, I2 = 13%) 0.26
(2.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27] 0.33
(2.4) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32] 0.15
(3) Myocardial infarction
(3.1) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 0.39
(3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28] 0.95
(3.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27] 0.2
(4) Revascularization
(4.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 0.67
(4.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28] 1.14
(5) Rehospitalization
(5.1) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al 2008 [28] 1.02
(5.2) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27] 0.2